Umbilical Cord vs Bone Marrow Stem Cells for Cartilage Repair

When it comes to repairing cartilage, umbilical cord-derived stem cells (hUC-MSCs) stand out compared to bone marrow-derived stem cells (BM-MSCs). Here’s why:

• Umbilical cord stem cells are collected safely at birth and maintain high quality regardless of age.
• Bone marrow stem cells require a surgical procedure for collection, and their effectiveness decreases as donors age.
• hUC-MSCs multiply 1,000 times faster and are 3x more likely to turn into cartilage-producing cells (chondrocytes).
• Clinical studies show hUC-MSCs regenerate cartilage that closely resembles natural tissue, while BM-MSCs often produce less durable fibrocartilage.

Key Findings:

• hUC-MSCs create better cartilage quality (hyaline-like) compared to BM-MSCs.
• They are easier to collect and store, making them more accessible for treatment.
• Both options improve pain and joint function, but umbilical cord cells offer longer-lasting benefits.

Quick Comparison

Feature	Umbilical Cord Stem Cells (hUC-MSCs)	Bone Marrow Stem Cells (BM-MSCs)
Collection Method	Non-invasive, at birth	Surgical procedure
Cell Quality	Consistent, neonatal quality	Declines with age
Proliferation	1,000x faster growth	Slower growth
Cartilage Regeneration	Hyaline-like cartilage	Fibrocartilage
Availability	Pre-collected, off-the-shelf	Same-day harvest required

Both types of stem cells have their place in regenerative medicine, but umbilical cord stem cells offer better scalability and more effective cartilage repair, making them a strong choice for future treatments.

How Stem Cells Repair Cartilage

Mesenchymal stem cells (MSCs) don’t just replace damaged cartilage - they kickstart a complex repair process. One key way they work is by transforming into chondrocytes, the cells responsible for producing cartilage. This transformation is controlled by SOX9, a transcription factor that drives the production of type II collagen (COL2A1) and aggrecan (ACAN). These two components are the backbone of cartilage, giving it both strength and cushioning. Growth factors, particularly those from the TGF-β superfamily and BMP-2, play a big role in enhancing this process.

But MSCs don’t stop at simply becoming cartilage cells. They also act as "Medicinal Signaling Cells," releasing signals that influence their surroundings. These signals help reduce inflammation and draw in other repair cells. They even encourage the joint’s own cells to migrate to the damaged area and multiply, creating a more coordinated healing effort.

"MSCs serve as dynamic and site-regulated entities within the body, acting as specialized 'depots' that release trophic and immunomodulatory factors. Instead of primarily engaging in tissue formation, MSCs are posited to play a pivotal role in local injury responses." - J. Pers. Med.

This dual function allows MSCs to both repair damaged tissue and control inflammation. Their anti-inflammatory abilities are just as important as their tissue-regenerating powers. MSCs suppress pro-inflammatory cytokines like IL-1β, TNF-α, and IL-6 while increasing anti-inflammatory agents such as IL-10 and TGF-β1. They also help shift macrophages (a type of immune cell) from a pro-inflammatory M1 state to a tissue-repairing M2 state. For example, a study published in August 2023 in Nature Scientific Reports tested three weekly injections of 2 × 10⁶ umbilical cord MSCs (a type of newborn stem cell) in rats with osteoarthritis. The results? Lower levels of IL-1β and TNF-α in joint fluid, fewer dying chondrocytes, and better overall joint health.

MSCs also protect cartilage by increasing anti-apoptotic proteins like Bcl-2, which prevent cell death, and by suppressing enzymes such as ADAMTS-5 and MMP-13 that break down the cartilage matrix. Interestingly, culturing MSCs under low oxygen conditions (about 8% O₂) further boosts their ability to express chondrogenic markers and produce proteoglycans, enhancing their cartilage-repairing potential even more.

Bone Marrow Stem Cells for Cartilage Repair

Collection and Availability

Bone marrow stem cells are extracted from the iliac crest (hip bone) through a surgical procedure that can be done under local or general anesthesia. Once collected, the raw bone marrow is processed to create Bone Marrow Aspirate Concentrate (BMAC). This concentrate contains around 19 million mononuclear cells, but only a very small fraction - 0.001% to 0.01% - are mesenchymal stem cells (MSCs).

"The number of collected MSCs may vary depending on the patient's age and general condition. MSCs from elderly patients have lower differentiation levels and chondrogenicity in vitro." - Myung Ku Kim, Department of Orthopedic Surgery, Inha University Hospital

While many parents choose cord blood banking to avoid invasive collection methods, bone marrow extraction remains a common alternative. The procedure itself poses certain challenges. Being invasive, it carries risks like chronic pain, hematoma, infections, and even fractures. Some patients may experience long-term pain requiring neuropathic medication. Another hurdle is that both the quantity and quality of MSCs decrease significantly with age, making the process less effective for older donors.

These difficulties in harvesting not only affect the safety of the procedure but also influence the overall effectiveness of BMAC treatments.

Clinical Outcomes and Applications

The low yield of MSCs and the complications tied to donor factors directly impact clinical outcomes. Still, BMAC treatments have shown promising results in improving pain and joint function. For instance, a retrospective study conducted at Inha University Hospital between March 2012 and October 2017 evaluated 25 knees treated with BMAC. Patients' IKDC subjective scores improved significantly, rising from a preoperative average of 44.17 to 80.27 after two years. MRI results indicated that 80% of patients experienced complete filling of cartilage lesions during this period.

In another study from 2011, researcher Alberto Gobbi treated 15 patients with severe cartilage damage (average age 48) using BMAC embedded in a collagen matrix. Histological analysis of three samples at the two-year mark confirmed the formation of hyaline-like tissue. A major benefit of BMAC is its single-stage approach: cells are collected, processed, and applied in one operation, eliminating the need for expensive, multi-stage procedures characteristic of cultured cell techniques.

Long-term safety data also supports the use of BMAC. One study followed 41 patients (45 transplantations) for up to 137 months (average 75 months) and found no cases of tumors or infections. While MRI and histology confirm cartilage repair and improved joint function, the repaired tissue often forms fibrocartilage, which is less durable than hyaline cartilage. Nonetheless, these outcomes highlight the potential of BMAC in addressing cartilage damage while maintaining a favorable safety profile.

Umbilical Cord Stem Cells for Cartilage Repair

Collection and Availability

Umbilical cord stem cells are collected right after birth from the umbilical cord and placenta, once the cord is clamped and cut. This process is completely safe for both mother and baby, as it uses tissue that would otherwise be discarded.

What makes these cells stand out is their abundance and growth potential. On average, trained professionals can collect about 110 ml of blood from a single placenta. Even more impressive, umbilical cord mesenchymal stem cells (hUC-MSCs) multiply over 1,000 times faster than bone marrow stem cells in bioreactors. Starting with just 1 million hUC-MSCs, you can produce 10 billion cells in four weeks, providing enough for multiple treatments.

These cells also have a low risk of immune rejection. They express minimal MHC class I and no MHC class II molecules, and they lack costimulatory molecules like CD40, CD80, and CD86. This makes them perfect for "off-the-shelf" allogeneic treatments, eliminating the need for a donor match. Unlike bone marrow stem cells, which require invasive harvesting at the time of need, umbilical cord stem cells can be prepared in advance as standardized, high-quality products.

"Wharton's jelly mesenchymal stem cells (WJ-MSCs) have become the first choice for cartilage regeneration engineering owing to their availability and convenience of collection." - Hanguang Liang, Researcher

Another major benefit is their ability to differentiate. hUC-MSCs are three times more likely than bone marrow stem cells to become chondrocytes, the specialized cells that form cartilage. This makes them a strong candidate for clinical applications in cartilage repair.

Clinical Outcomes and Applications

Clinical research shows that umbilical cord stem cells outperform traditional methods in cartilage repair. One key advantage is the type of cartilage they regenerate. While bone marrow treatments often produce fibrocartilage, which is less durable, hUCB-MSCs generate hyaline-like cartilage, closely mimicking natural cartilage. In a Phase 3 trial, 97.7% of patients treated with hUCB-MSCs improved by at least one International Cartilage Repair Society (ICRS) grade within 48 weeks, compared to just 71.7% in the microfracture group.

From 2015 to 2019, a study analyzed 39 patients undergoing cartilage repair using the AMIC technique with either hUCB-MSCs or bone marrow aspirate concentrate (BMAC). Despite the hUCB-MSC group being older and having larger lesions - 568 mm² on average versus 336 mm² in the BMAC group - they achieved similar clinical results at the 12-month follow-up, proving effective even in more challenging cases.

"HUC-MSCs possess the ability to alleviate pain, enhance knee joint function, and potentially postpone the need for surgical intervention... making them highly deserving of clinical promotion and application." - Journal of Orthopaedic Surgery and Research

Safety data supports their long-term use, with improvements in pain and joint function lasting up to 7 years and no severe side effects reported. These cells work by releasing factors that encourage joint cell regeneration and shift macrophages from an inflammatory state (M1) to a healing state (M2).

The Role of Cord Blood Banking

Given these benefits, banking umbilical cord-derived cells is a proactive step for long-term joint health. Cord blood banking ensures access to these cells at their peak quality, as newborn stem cells are "younger" and haven't been exposed to environmental damage or aging.

Americord Registry specializes in preserving these cells with CryoMaxx™ Processing, designed to maintain mesenchymal stem cell quality for future regenerative treatments like cartilage repair. Their services include options for storing cord tissue (Wharton's Jelly), cord blood, and placental tissue, supported by a $110,000 engraftment guarantee.

When stored in liquid nitrogen at -195°F, these cells stay viable for decades, offering a long-term solution for conditions like osteoarthritis, which affects over 10% of people globally aged 60 and above.

"When you bank your baby's stem cells and perinatal tissues, you are giving them a key to unlocking and accessing new treatment options, for their entire life." - Americord Registry

Banking also provides a potential treatment source for family members, as stored cells are a genetic match for the donor and may be compatible with close relatives. With over 80 FDA-approved treatments and more than 300 clinical trials exploring newborn stem cells, cord blood banking is a smart investment in future health and regenerative medicine advancements.

Bone Marrow vs Umbilical Cord Stem Cells: Direct Comparison

Clinical Effectiveness and Safety

When comparing pain relief and joint function, bone marrow aspirate concentrate (BMAC) and umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) show similar outcomes. A study conducted in July 2020 by Dong Jin Ryu and colleagues at Inha University Hospital in Korea followed 52 patients for two years. Pain scores (VAS) improved from 5.2 to 0.92 for BMAC patients and from 5.0 to 0.85 for hUCB-MSC patients, revealing no significant difference between the two groups.

The key difference lies in cartilage regeneration quality. A March 2023 meta-analysis led by Dojoon Park reviewed 499 patients (169 BMAC, 330 hUCB-MSCs) undergoing high tibial osteotomy. While clinical outcomes were comparable, hUCB-MSCs showed better cartilage regeneration on second-look arthroscopy (p < 0.001). This improvement in structural repair suggests longer-lasting benefits.

"Compared with BMAC injection, intra-articular hUCB-MSCs can induce significantly better tissue repair at 1 year after surgery, as assessed by the ICRS grade."
– P.-F. Wang and J. Xing, Department of Orthopedics, Honghui Hospital

In terms of safety, both treatments have similar profiles. In the 52-patient study, postoperative adhesions occurred in 8% of BMAC cases (2 patients) and 11% of hUCB-MSC cases (3 patients). Neither group faced major complications like deep infections or immediate knee replacement surgery. However, the collection process differs significantly: BMAC involves bone aspiration under anesthesia, which carries risks like donor site pain and infection. In contrast, hUCB-MSCs are readily available as an off-the-shelf product, eliminating these risks. These differences set the stage for exploring the practical aspects of harvesting and scalability.

Practical Considerations

The collection methods for these treatments highlight a critical advantage of hUCB-MSCs. BMAC requires an invasive procedure, with risks such as donor site pain and infection. Meanwhile, hUCB-MSCs are collected non-invasively at birth and are available off-the-shelf.

Age impacts the effectiveness of BMAC, but not hUCB-MSCs. A February 2024 study in the Journal of Personalized Medicine compared 39 patients and found that, despite the hUCB-MSC group being older (average age 53.8 years vs. 44.1 years) and having larger cartilage defects (5.68 cm² vs. 3.36 cm²), clinical outcomes at 12 months were comparable. This indicates that hUCB-MSCs maintain consistent quality regardless of patient age, unlike BMAC.

Feature	Bone Marrow (BMAC)	Umbilical Cord (hUCB-MSCs)
Collection Method	Invasive aspiration from bone	Non-invasive; collected at birth
Patient Pain/Risk	Requires anesthesia; donor site morbidity	No risk to patient
Cell Quality	Declines with patient age	Uniform, neonatal quality
Expansion Speed	Slower proliferation	1,000 times faster proliferation
Availability	Same-day harvest required	Off-the-shelf; can be banked
Regeneration Quality	Good (often fibrocartilage)	Superior (hyaline-like cartilage)

When it comes to scalability, hUCB-MSCs are the clear winner. Starting with just 1 million hUCB-MSCs, labs can generate 10 billion cells in four weeks, enough for multiple treatments. BMAC, on the other hand, yields fewer cells, making it less suitable for repeated or large-scale use.

"hUCB-MSCs have the advantage of low donor site morbidity, no need for preparation procedures, and uniform cell count and quality."
– Dong Jin Ryu, Department of Orthopedic Surgery, Inha University

Both treatments support one-stage procedures, allowing patients to receive treatment in a single surgery. However, BMAC adds the time and trauma of cell collection, while hUCB-MSCs eliminate this step entirely. For those who understand cord blood banking benefits and have banked samples, hUCB-MSCs provide an accessible, long-term option without invasive harvesting. This convenience and scalability make hUCB-MSCs a promising choice for broader clinical use. As research evolves, lifetime storage of stem cells ensures these regenerative options remain available for decades.

Current and Future Applications

FDA-Approved Therapies and Clinical Trials

The landscape of cartilage repair is constantly evolving, with clinical trials and regulatory developments shaping the available treatments. In the United States, hUC-MSC (human umbilical cord mesenchymal stem cell) therapies for knee osteoarthritis are currently limited to FDA-approved clinical trials. Because of this, many Americans turn to international clinics, where treatments can cost anywhere from $8,000 to $30,000.

One notable example of an approved therapy is Cartistem®, which has been available in South Korea since 2012. This allogeneic treatment combines hUC-MSCs with hyaluronate. A Phase 3 trial conducted between February 2009 and January 2011 involving 114 patients demonstrated impressive results: 97.7% of participants treated with the UCB-MSC-HA composite showed at least a one-grade improvement on the ICRS scale at 48 weeks, compared to 71.7% of those treated with microfracture. The benefits of this therapy lasted up to five years, with regenerated cartilage maintaining durability for 3–7 years.

In the U.S., BMAC (bone marrow aspirate concentrate) is another option available under HCT/P regulations. However, its use is limited due to the invasive nature of the collection process and the decline in cell quality as donors age. These regulatory and practical differences highlight the challenges clinicians face in balancing treatment effectiveness with accessibility.

Americord Registry's Regenerative Medicine Services

As research and regulations continue to advance, banking umbilical cord tissues has become a critical step in preparing for future regenerative therapies. Americord Registry provides families with the option to store umbilical cord tissue, which is a rich source of mesenchymal stem cells widely used in orthopedic research. Using their CryoMaxx™ Processing technology, Americord ensures that the stored tissue retains its quality, with stem cells preserved in liquid nitrogen, remaining viable for decades.

In addition to cord tissue, Americord also offers the storage of cord blood, placental tissue, and newborn exosomes. These exosomes represent an emerging, cell-free option in regenerative medicine. The company backs its services with a $110,000 engraftment guarantee, reflecting their commitment to quality and reliability. For families choosing to bank their newborn's stem cells today, this decision could open doors to advanced cartilage repair therapies in the future. With the ability to expand stored samples, a single collection may support multiple treatments over a person’s lifetime, offering a glimpse into the promising future of regenerative medicine.

Conclusion

When it comes to cartilage repair, the evidence leans heavily in favor of umbilical cord-derived stem cells. While both umbilical cord-derived and bone marrow-derived stem cells show promise, umbilical cord-derived mesenchymal stem cells (hUC-MSCs) consistently outperform in critical areas. Studies show that 71.2%–81.3% of patients achieve normal or nearly normal cartilage quality with hUC-MSCs, compared to just 40%–56.8% with bone marrow-derived cells. These neonatal cells are also three times more likely to develop into chondrocytes and can proliferate over 1,000 times faster in lab conditions - making them a resource that can support multiple treatments from a single collection.

Accessibility is another major advantage. Bone marrow extraction is invasive and becomes less effective as donors age. In contrast, umbilical cord stem cells are collected non-invasively from tissue that would otherwise be discarded. Their immune-privileged status also allows for immediate, ready-to-use applications without the need for invasive procedures.

"When you bank your baby's stem cells and perinatal tissues, you are giving them a key to unlocking and accessing new treatment options, for their entire life." - Americord Registry

FAQs

Who is a good candidate for umbilical cord stem cell cartilage repair?

Ideal candidates for this therapy are active individuals under the age of 55 who are dealing with cartilage damage caused by injuries, trauma, or conditions such as osteoarthritis. It’s especially beneficial for those experiencing chronic knee pain or dealing with articular cartilage lesions, with the goal of improving joint function and postponing more invasive surgical options. To determine if this treatment is right for you, a specialist will assess factors like your activity level, age, and the severity of your injury.

How long do cartilage repair results typically last?

Cartilage repair typically holds up for at least 2 years, with both clinical evaluations and MRI scans indicating solid repair and stability throughout this period. However, results can differ based on personal health factors and the details of the treatment used.

Are umbilical cord stem cell treatments FDA-approved in the U.S.?

No, umbilical cord stem cell treatments are not FDA-approved in the United States for cartilage repair or any other medical conditions. While stem cells show potential in regenerative medicine, their application for these treatments is still considered experimental and has not received FDA authorization.